Lin, Y., Raje, N. S., Berdeja, J. G., et al. (2023). Idecabtagene vicleucel for relapsed and refractory multiple myeloma: Post hoc 18-month follow-up of a phase 1 trial. Nature Medicine, 29, 2286–2294.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raje, N., Berdeja, J., Lin, Y., et al. (2019). Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine, 380, 1726–1737.

Article  CAS  PubMed  Google Scholar 

Munshi, N. C., Anderson, L. D., Shah, N., et al. (2021). Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384, 705–716.

Article  CAS  PubMed  Google Scholar 

Berdeja, J. G., Raje, N. S., Siegel, D. S., et al. (2020). Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients with relapsed and refractory multiple myeloma: KarMMa subgroup analysis. Blood, 136, 16–17.

Article  Google Scholar 

Hansen, D. K., Sidana, S., Peres, L. C., et al. (2023). Idecabtagene Vicleucel for relapsed/refractory multiple myeloma: Real-world experience from the myeloma CAR T consortium. Journal of Clinical Oncology, 41, 2087–2097.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferreri, C. J., Hildebrandt, M. A. T., Hashmi, H., et al. (2023). Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer Journal, 13, 117.

Article  PubMed  PubMed Central  Google Scholar 

Berdeja, J. G., Madduri, D., Usmani, S. Z., et al. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. Lancet, 398, 314–324.

Article  CAS  PubMed  Google Scholar 

Martin, T., Usmani, S. Z., Berdeja, J. G., et al. (2023). Ciltacabtagene Autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. Journal of Clinical Oncology, 41, 1265–1274.

Article  CAS  PubMed  Google Scholar 

Hansen, D. K., Patel, K. K., Peres, L. C., et al. (2023). Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology, 41, 8012–8012.

Article  Google Scholar 

San-Miguel, J., Dhakal, B., Yong, K., et al. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. New England Journal of Medicine, 389, 335.

Article  CAS  PubMed  Google Scholar 

Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., et al. (2023). Ide-cel or standard regimens in relapsed and refractory multiple myeloma. New England Journal of Medicine, 388, 1002–1014.

Article  CAS  PubMed  Google Scholar 

Kumar, S. K., Rajkumar, V., Kyle, R. A., et al. (2017). Multiple myeloma. Nature Reviews Disease Primers, 3, 17046.

Article  PubMed  Google Scholar 

Kumar, S., Paiva, B., Anderson, K. C., et al. (2016). International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology, 17, e328–e346.

Article  PubMed  Google Scholar 

Rajkumar, S. V., & Kumar, S. (2016). Multiple myeloma: Diagnosis and treatment. Mayo Clinic Proceedings, 91, 101–119.

Article  PubMed  Google Scholar 

Terpos, E., Mikhael, J., Hajek, R., et al. (2021). Management of patients with multiple myeloma beyond the clinical-trial setting: Understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 11, 40.

Article  PubMed  PubMed Central  Google Scholar 

Lim, W. A., & June, C. H. (2017). The principles of engineering immune cells to treat cancer. Cell, 168, 724–740.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 17, 147–167.

Article  PubMed  Google Scholar 

Sadelain, M., RiviSre, I., & Riddell, S. (2017). Therapeutic T cell engineering. Nature, 545, 423–431.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Srivastava, S., & Riddell, S. R. (2015). Engineering CAR-T cells: Design concepts. Trends in Immunology, 36, 494–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11, 69.

Article  PubMed  PubMed Central  Google Scholar 

Ali, S. A., Shi, V., Maric, I., et al. (2016). T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood, 128, 1688–1700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., et al. (2024). GPRC5D as a novel target for the treatment of multiple myeloma: A narrative review. Blood Cancer Journal, 14, 24.

Article  PubMed  PubMed Central  Google Scholar 

Mikkilineni, L., & Kochenderfer, J. N. (2021). CAR T cell therapies for patients with multiple myeloma. Nature Reviews. Clinical Oncology, 18, 71–84.

Article  CAS  PubMed  Google Scholar 

Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., et al. (2013). B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research, 19, 2048–2060.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Novak, A. J., Darce, J. R., Arendt, B. K., et al. (2004). Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood, 103, 689–694.

Article  CAS  PubMed  Google Scholar 

O’Connor, B. P., Raman, V. S., Erickson, L. D., et al. (2004). BCMA is essential for the survival of long-lived bone marrow plasma cells. Journal of Experimental Medicine, 199, 91–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mikkilineni, L., Natrakul, D. A., Lam, N., et al. (2024). Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. Molecular Therapy, 32, 503–526.

Article  CAS  PubMed  Google Scholar 

Brudno, J. N., Maric, I., Hartman, S. D., et al. (2018). T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. Journal of Clinical Oncology, 36, 2267–2280.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith, E. L., Harrington, K., Staehr, M., et al. (2019). GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine, 11, eaau7746.

Article  PubMed  PubMed Central  Google Scholar 

Bal, S., Htut, M., Nadeem, O., et al. (2023). BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Updated results from a phase 1 study. Blood, 142, 219.

Article  Google Scholar 

Chari, A., Minnema, M. C., Berdeja, J. G., et al. (2022). Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. New England Journal of Medicine, 387, 2232–2244.

Article  CAS